Morgan Stanley Vanda Pharmaceuticals Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Morgan Stanley holds 900,477 shares of VNDA stock, worth $4.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

900,477

Previous 916,720 1.77%

Holding current value

$4.8 Million

Previous $4.21 Million 1.02%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$3.92 - $4.82 $63,672 - $78,291	-16,243 Reduced 1.77%	900,477 $4.25 Million
Q1 2025 May 15, 2025	SELL	$4.31 - $5.13 $1.83 Million - $2.17 Million	-423,783 Reduced 31.61%	916,720 $4.21 Million
Q4 2024 Feb 14, 2025	BUY	$4.41 - $5.46 $3.19 Million - $3.95 Million	724,082 Added 117.47%	1,340,503 $6.42 Million
Q3 2024 May 14, 2025	BUY	$4.61 - $6.34 $549,516 - $755,734	119,201 Added 23.97%	616,421 $2.89 Million
Q3 2024 Nov 14, 2024	BUY	$4.61 - $6.34 $549,516 - $755,734	119,201 Added 23.97%	616,421 $2.89 Million
Q2 2024 May 14, 2025	SELL	$3.91 - $6.5 $3.3 Million - $5.48 Million	-843,283 Reduced 62.91%	497,220 $2.81 Million
Q2 2024 Oct 17, 2024	SELL	$3.91 - $6.5 $3.95 Million - $6.57 Million	-1,011,428 Reduced 67.04%	497,220 $2.81 Million
Q2 2024 Aug 14, 2024	SELL	$3.91 - $6.5 $3.95 Million - $6.57 Million	-1,011,428 Reduced 67.04%	497,220 $2.81 Million
Q1 2024 Oct 17, 2024	BUY	$3.47 - $4.61 $3.51 Million - $4.66 Million	1,011,428 Added 203.42%	1,508,648 $6.2 Million
Q1 2024 Aug 16, 2024	SELL	$3.47 - $4.61 $1.78 Million - $2.37 Million	-514,320 Reduced 25.42%	1,508,648 $6.2 Million
Q1 2024 May 15, 2024	SELL	$3.47 - $4.61 $1.78 Million - $2.37 Million	-514,320 Reduced 25.42%	1,508,648 $6.2 Million
Q4 2023 Aug 16, 2024	BUY	$3.38 - $4.58 $5.16 Million - $6.99 Million	1,525,748 Added 306.86%	2,022,968 $8.54 Million
Q4 2023 Feb 13, 2024	BUY	$3.38 - $4.58 $1.46 Million - $1.98 Million	433,338 Added 27.26%	2,022,968 $8.54 Million
Q3 2023 Nov 15, 2023	BUY	$4.28 - $6.57 $2.54 Million - $3.9 Million	592,987 Added 59.5%	1,589,630 $6.87 Million
Q2 2023 Aug 14, 2023	SELL	$5.9 - $6.95 $1.49 Million - $1.76 Million	-252,963 Reduced 20.24%	996,643 $6.57 Million
Q1 2023 May 15, 2023	BUY	$6.18 - $7.99 $2.88 Million - $3.72 Million	465,655 Added 59.4%	1,249,606 $8.48 Million
Q4 2022 Feb 14, 2023	BUY	$6.87 - $10.96 $2.02 Million - $3.23 Million	294,678 Added 60.23%	783,951 $5.79 Million
Q3 2022 Nov 14, 2022	SELL	$9.44 - $11.76 $1.74 Million - $2.17 Million	-184,765 Reduced 27.41%	489,273 $4.83 Million
Q2 2022 Oct 27, 2022	BUY	$9.31 - $11.84 $2.43 Million - $3.09 Million	261,061 Added 63.21%	674,038 $7.35 Million
Q2 2022 Aug 15, 2022	BUY	$9.31 - $11.84 $2.43 Million - $3.09 Million	261,061 Added 63.21%	674,038 $7.35 Million
Q1 2022 Oct 27, 2022	SELL	$10.84 - $16.55 $2.83 Million - $4.32 Million	-261,061 Reduced 38.73%	412,977 $4.67 Million
Q1 2022 May 13, 2022	BUY	$10.84 - $16.55 $1.34 Million - $2.05 Million	123,588 Added 42.71%	412,977 $4.67 Million
Q4 2021 Feb 14, 2022	BUY	$15.69 - $21.14 $653,457 - $880,438	41,648 Added 16.81%	289,389 $4.54 Million
Q3 2021 Nov 15, 2021	BUY	$15.35 - $21.27 $3.8 Million - $5.27 Million	247,741 New	247,741 $4.25 Million

Others Institutions Holding VNDA

# of Institutions

150

Shares Held

45.3M

Call Options Held

20K

Put Options Held

999K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $301M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account